Tapentadol: With two mechanisms of action in one molecule effective against nociceptive and neuropathic pain: Preclinical overview;Tapentadol: Mit zwei Mechanismen in einem Molekül wirksam gegen nozizeptive und neuropathische Schmerzen: Präklinischer Überblick

Schmerz

Volumn 25, Issue 1, 2011, Pages 19-25

  Tzschentke, T M ^a   Christoph, T ^a   Schroder W ^a   Englberger, W ^a   De Vry, J ^a   Jahnel, U ^a   Kogel B Y ^a  

^a GRÜNENTHAL GMBH   (Germany)

Author keywords

Neuropathic pain; Neurotransmitter uptake inhibitors; Nociceptive pain; Receptors, Opioid, mu; Tapentadol

Indexed keywords

MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NORADRENALIN UPTAKE INHIBITOR; TAPENTADOL;

ARTICLE; CHRONIC PAIN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; INFLAMMATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN;

ADRENERGIC UPTAKE INHIBITORS; ANALGESICS, OPIOID; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MORPHINE; NEURALGIA; NOCICEPTORS; NOREPINEPHRINE; PAIN MEASUREMENT; PHENOLS; RECEPTORS, OPIOID, MU; SPINAL CORD;

EID: 79952315355     PISSN: 0932433X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00482-010-1004-1     Document Type: Article

References (25)

1. Bannister K, Bee LA, Dickenson AH (2009) Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurother 6:703-712
2. Christoph T, De Vry J, Tzschentke TM (2010a) Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Neurosci Lett 470:91-94
3. Christoph T, De Vry J, Tzschentke TM (2010b) Synergistic interaction of tapentadol and pregabalin in a rat model of neuropathic pain. Proceedings of the 13th Biennial World Congress on Pain (IASP 2010); August 29 - September 2, 2010; Montreal, Quebec, Canada; abstract PH186
4. Daniels SE, Upmalis D, Okamoto A et al (2009) A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 25:765-776
5. Hale M, Upmalis D, Okamoto A et al (2009) Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double blind study. Curr Med Res Opin 25:1095-1104
6. Kalso E, Edwards JE, Moore RA, McQuay HJ (2004) Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 112:372-380 (Pubitemid 39550738)
7. Kieffer BL (1999) Opioids: First lessons from knockout mice. Trends Pharmacol Sci 20:19-26 (Pubitemid 29304521)
8. Klotz U (2003) Tramadol - the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung/Drug Res 53:681-687 (Pubitemid 37357353)
9. Kneip C, Terlinden R, Beier H, Chen G (2008) Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett 2:67-75 (Pubitemid 351411265)
10. Kgel BY, De Vry T, Tzschentke TM, Christoph T (2010) The anti-nociceptive and anti-hyperalgesic efficacy of Tapentadol is partially retained in OPRM1 (?-opioid receptor) knockout mice. Proceedings of the 13th Biennial World Congress on Pain (IASP 2010); August 29 - September 2, 2010; Montreal, Quebec, Canada; abstract PM183
11. Lange B, Kuperwasser B, Okamoto A et al (2010) Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 27:381-399
12. Mic JA, Ardid D, Berrocoso E, Eschalier A (2006) Antidepressants and pain. Trends Pharmacol Sci 27:348-353
13. Millan MJ (2002) Descending control of pain. Prog Neurobiol 66:355-474 (Pubitemid 34606906)
14. Ossipov MH, Malseed RT, Goldstein FJ (1982) Augmentation of central and peripheral morphine analgesia by desipramine. Arch Int Pharmacodyn Ther 259:222-229 (Pubitemid 13244037)
15. Ossipov MH, Harris S, Lloyd P, Messineo E (1990) An isobolographic analysis of the antinociceptive effect of systemically and intrathecally administered combinations of clonidine and opiates. J Pharmacol Exp Ther 255:1107-1116
16. Ossipov MH, Lopez Y, Bian D et al (1997) Synergistic antinociceptive interactions of morphine and clonidine in rats with nerve-ligation injury. Anesthesiology 86:196-204 (Pubitemid 27045733)
17. Raffa RB, Friderichs E (1996) The basic science aspect of tramadol hydrochloride. Curr Rev Pain 3:249-271 (Pubitemid 27013231)
18. Raffa RB, Nayak RK, Liao S, Minn FL (1995) The mechanism(s) of action and pharmacokinetics of tramadol hydrochloride. Rev Contemp Pharmacother 6:485-497
19. Schrder W, De Vry J, Tzschentke TM et al (2010) Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 14:814-821
20. Smith HS (2008) Combination opioid analgesics. Pain Physician 11:201-214 (Pubitemid 351546231)
21. Suzuki R, Rygh LJ, Dickenson AH (2004) Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci 25:613-617 (Pubitemid 39458166)
22. Terlinden R, Kgel B, Englberger W, Tzschentke TM (2010) In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol 32(1):31-38
23. Tzschentke TM, De Vry J, Terlinden R et al (2006) Tapentadol HCl. Drugs Future 31:1053-1061
24. Tzschentke TM, Christoph T, Kgel B et al (2007) (-)-(1R,2R)-3-(3- Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel m opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 323:265-276 (Pubitemid 47443277)
25. Tzschentke TM, Jahnel U, Kgel B et al (2009) Tapentadol hydrochloride: a next generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today 45:483-496